Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Raciol is a specific variety of oilseed flax (*Linum usitatissimum* L.) of Czech origin, characterized by its high content of alpha-linolenic acid (ALA) and phenolic compounds such as lignans. It is utilized as a functional food or nutraceutical to mitigate cardiovascular risk factors, particularly in postmenopausal women. The variety's mechanism involves the systemic reduction of inflammatory markers like high-sensitivity C-reactive protein (hs-CRP) and the improvement of lipid profiles, specifically by reducing LDL cholesterol and increasing HDL cholesterol. Its bioactive components, such as secoisolariciresinol diglucoside (SDG), act as phytoestrogens and antioxidants, while its high fiber and omega-3 fatty acid content contribute to metabolic health. In clinical research, Raciol is often categorized as a low-lignan variety compared to other cultivars like Agram.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Raciol.